Treatment of early-stage HER2+ breast cancer-an evolving field

被引：8

作者：

Ferreira, Arlindo R. ^{[1
,2
,3
]}

Saini, Kamal S. ^{[4
]}

Metzger-Filho, Otto ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02215 USA

[2] Univ Lisbon, Hosp Santa Maria, P-1649035 Lisbon, Portugal

[3] Univ Lisbon, Inst Med Mol, P-1649035 Lisbon, Portugal

[4] Univ Libre Bruxelles, Inst Jules Bordet, B-1000 Brussels, Belgium

来源：

ECANCERMEDICALSCIENCE | 2015年 / 9卷

关键词：

breast neoplasm; trastuzumab; neoadjuvant therapy; adjuvant therapy; antibodies; monoclonal; humanised;

D O I：

10.3332/ecancer.2015.523

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The evolving field of HER2-targeted therapy has significantly improved the outcome of women diagnosed with HER2-positive invasive breast cancer. In this review, we sought to summarise the efficacy of trastuzumab-based regimens in the adjuvant and neoadjuvant setting with a special emphasis on relevant clinical questions: treatment duration, sequence of trastuzumab administration, toxicity, the role of anthracycline-based regimens, and optimal management of small HER2+ tumours. Controversial topics are discussed taking into consideration the development of modern anti-HER2 agents.

引用

页数：15

共 50 条

[1] Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer?
Maltoni, Roberta
Palleschi, Michela
Altini, Mattia
Massa, Ilaria
Balzi, William
Ravaioli, Sara
Tumedei, Maria Maddalena
Rocca, Andrea
Bravaccini, Sara
CLINICAL BREAST CANCER, 2020, 20 (04) : 359 - 360
[2] Advances in the Treatment of Early-Stage HER2-Positive Breast Cancer
Sharifi, Marina
Wisinski, Kari B.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (08) : 482 - 492
[3] The prognostic performance of PREDICT plus in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).
Agostinetto, Elisa
Ameye, Lieveke
Martel, Samuel
Aftimos, Philippe Georges
Ponde, Noam
Maurer, Christian
El-Abed, Sarra
Wang, Yingbo
Vicente, Maria Lourdes
Chumsri, Saranya
Bliss, Judith
Kroep, Judith R.
Colleoni, Marco
Petrelli, Fausto
Del Mastro, Lucia
Moreno-Aspitia, Alvaro
Piccart-Gebhart, Martine J.
Paesmans, Marianne
De Azambuja, Evandro
Lambertini, Matteo
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Treatment landscape of patients with HER2+ early breast cancer: an overview
Ting, Frederic Ivan L.
ECANCERMEDICALSCIENCE, 2024, 18
[5] The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer
Ryan, PD
Goss, PE
NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (12): : 596 - 597
[6] The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer
Paula D Ryan
Paul E Goss
Nature Clinical Practice Oncology, 2005, 2 : 596 - 597
[7] Pertuzumab in the Treatment of HER2+ Breast Cancer
Jhaveri, Komal
Esteva, Francisco J.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (04): : 591 - 598
[8] Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report
Wade Iams
Kathyrn Eby Beckermann
Anne T. Neff
Ingrid A. Mayer
Vandana Gupta Abramson
Medical Oncology, 2013, 30
[9] Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer
Sanfeliu, Esther
Braso-Maristany, Fara
Dieci, Maria Vittoria
Marin-Aguilera, Mercedes
Gonzalez-Farre, Blanca
Griguolo, Gaia
Pascual, Tomas
Galvan, Patricia
Angelats, Laura
Castillo, Oleguer
Blasco, Paula
Sirenko, Valeria
Jares, Pedro
Puig-Butille, Joan Anton
Pare, Laia
Martinez, Antonio
Llombart-Cussac, Antonio
Cortes, Javier
Vivancos, Ana
Villagrasa, Patricia
Parker, Joel S.
Perou, Charles M.
Prat, Aleix
Conte, PierFranco
Guarneri, Valentina
CANCER RESEARCH, 2023, 83 (05)
[10] Targeting HER2 heterogeneity in early-stage breast cancer
Pernas, Sonia
Tolaney, Sara M.
CURRENT OPINION IN ONCOLOGY, 2020, 32 (06) : 545 - 554

← 1 2 3 4 5 →